The 2022 ADA Standards of Medical Care in Diabetes and the KDIGO 2022 Clinical Practice Guideline provide evidence-based recommendations for managing diabetes and chronic kidney disease (CKD). These jointly reviewed guidelines emphasize comprehensive care, integrating proven pharmacotherapy with healthy lifestyle practices. Specific consensus statements offer guidance on drug usage, including renin-angiotensin system inhibitors, metformin, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist, with the goal of enhancing clinical outcomes for individuals with diabetes and CKD.
Despite alignment between the 2022 ADA Standards of Care and KDIGO 2022 guideline, challenges like high costs and limited healthcare resources may hinder broad implementation of these recommendations, necessitating efforts to improve accessibility and address disparities. Ongoing research in diabetes, CKD, and cardiovascular disease is anticipated to provide further insights, driving continual evolution of clinical practice guidelines.
Reference: de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075-3090. doi: 10.2337/dci22-0027. PMID: 36189689; PMCID: PMC9870667.
